MedTrace Logo

A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease

NCT00358683 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2012-05-28

No results posted yet for this study

Summary

The primary aim of this study is allow the patients suffering from Crohn's disease , who both completed the therapeutic confirmatory study C87055 of certolizumab pegol and benefited from the treatment, to receive treatment with certolizumab pegol until the drug is available for the Crohn's disease indication in Greece.

Conditions

Interventions

DRUG

Certolizumab pegol

Sponsors & Collaborators

  • UCB Pharma

    lead INDUSTRY

Principal Investigators

  • George Syrmalis, M.D. M.Sc. Ph.D. · UCB Pharma

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00358683 on ClinicalTrials.gov